Generic Zerbaxa Availability

Last updated on Apr 10, 2025.

Zerbaxa is a brand name of ceftolozane/tazobactam, approved by the FDA in the following formulation(s):

ZERBAXA (ceftolozane sulfate; tazobactam sodium - powder;intravenous)

• Manufacturer: CUBIST PHARMS LLC
  Approval date: December 19, 2014
  Strength(s): EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ^[RLD]

Is there a generic version of Zerbaxa available?

No. There is currently no therapeutically equivalent version of Zerbaxa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zerbaxa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods for treating intrapulmonary infections
  Patent 10,028,963
  Issued: July 24, 2018
  Inventor(s): Chandorkar Gurudatt A. & Huntington Jennifer A. & Parsons Tara & Umeh Obiamiwe C.
  Assignee(s): Merck Sharp & Dohme Corp.
  

  This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

  Patent expiration dates:

  • September 7, 2032
    
    ✓ 
    Patent use: TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
  • September 7, 2032
    
    ✓ 
    Patent use: TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
• Synthesis of cephalosporin compounds
  Patent 10,125,149
  Issued: November 13, 2018
  Inventor(s): Waller David & Gazda Gregory & Minden Zachary & Barton Lisa & Leigh Clifton
  Assignee(s): Merck Sharp & Dohme Corp.
  

  Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction. Provided herein are methods for the synthesis of cephalosporin compounds of formula (I) employing a palladium-catalyzed alkylation reaction, as well as compositions related to the same. In an aspect, provided herein is a method for preparing a compound of formula (II), or a salt thereof, comprising the step of admixing, e.g., reacting, a compound of formula (III), or a salt thereof, with a nucleophile (Nuc) in the presence of reagents comprising: (a) a palladium source; and (b) a palladium-binding ligand, to form a compound of formula (II), or a salt thereof.

  Patent expiration dates:

  • August 14, 2035
    
    ✓ 
    Drug product
• Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
  Patent 10,376,496
  Issued: August 13, 2019
  Inventor(s): Krishna Gopal & Chandorkar Gurudatt & Hershberger Elham & Miller Benjamin & Xiao Alan
  Assignee(s): Merck, Sharp & Dohme Corp.
  

  Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.

  Patent expiration dates:

  • September 9, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
  • September 9, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
• Ceftolozane antibiotic compositions
  Patent 10,420,841
  Issued: September 24, 2019
  Inventor(s): Terracciano Joseph & Damour Nicole Miller & Jiang Chun & Fogliato Giovanni & Donadelli Giuseppe Alessandron & Resemini Dario
  Assignee(s): Merck, Sharp & Dohme Corp.
  

  This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION
  • March 14, 2034
    
    ✓ 
    Patent use: COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
  • March 14, 2034
    
    ✓ 
    Patent use: COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
• Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
  Patent 10,933,053
  Issued: March 2, 2021
  Inventor(s): Krishna Gopal & Chandorkar Gurudatt & Hershberger Elham & Miller Benjamin & Xiao Alan
  Assignee(s): MERCK SHARP & DOHME CORP.
  

  Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.

  Patent expiration dates:

  • September 9, 2034
    
    ✓ 
    Patent use: TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
  • September 9, 2034
    
    ✓ 
    Patent use: TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
• Ceftolozane antibiotic compositions
  Patent 11,278,622
  Issued: March 22, 2022
  Inventor(s): Terracciano Joseph & Damour Nicole Miller & Jiang Chun & Fogliato Giovanni & Donadelli Giuseppe Alessandron & Resemini Dario
  Assignee(s): Merck Sharp & Dohme Corp.
  

  This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
• Cephem compounds
  Patent 7,129,232
  Issued: October 31, 2006
  Inventor(s): Ohki; Hidenori et al.
  Assignee(s): Astellas Pharma Inc. (Tokyo, JP); Wakunaga Pharmaceutical Co., Ltd (Osaka, JP)
  

  The present invention relates to a compound of the formula [I]: ##STR00001## wherein R.sup.1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R.sup.2 is hydrogen or amino protecting group, or R.sup.1 and R.sup.2 are bonded together and form lower alkylene or lower alkenylene; R.sup.3 is hydrogen or lower alkyl; R.sup.4 is ##STR00002## R.sup.5 is carboxy or protected carboxy; and R.sup.6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  Patent expiration dates:

  • May 15, 2028
    
    ✓ 
    Patent use: METHODS FOR TREATING BACTERIAL INFECTIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 15, 2028
    
    ✓ 
    Patent use: COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 15, 2028
    
    ✓ 
    Patent use: COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 15, 2028
    
    ✓ 
    Patent use: METHODS OF TREATING BACTERIAL ILLNESSES
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Tazobactam arginine compositions
  Patent 8,476,425
  Issued: July 2, 2013
  Inventor(s): Lai Jan-Ji & Gu Jian-Qiao & Pathare Pradip M. & Jurkauskas Valdas & Terracciano Joseph & Damour Nicole Miller
  Assignee(s): Cubist Pharmaceuticals, Inc.
  

  This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.

  Patent expiration dates:

  • September 27, 2032
    
    ✓ 
    Drug substance
• Tazobactam arginine compositions
  Patent 8,685,957
  Issued: April 1, 2014
  Inventor(s): Lai Jan-Ji & Gu Jian-Qiao & Pathare Pradip M. & Jurkauskas Valdas & Terracciano Joseph & Damour Nicole Miller
  Assignee(s): Cubist Pharmaceuticals, Inc.
  

  This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.

  Patent expiration dates:

  • September 27, 2032
    
    ✓ 
    Patent use: METHODS OF TREATING BACTERIAL ILLNESSES
    ✓ 
    Drug substance
• Solid forms of ceftolozane
  Patent 8,906,898
  Issued: December 9, 2014
  Inventor(s): Hwang You Seok & Damour Nicole Miller & Duong Lisa & Jurkauskas Valdas & Moshos Kristos Adrian & Mudur Sanjay & Ovat Asli & Terracciano Joseph & Woertink Jason
  Assignee(s): Calixa Therapeutics, Inc.
  

  Novel solid forms of ceftolozane are described, as well as methods for the preparation and use of these solid forms.

  Patent expiration dates:

  • May 28, 2034
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Ceftolozane-tazobactam pharmaceutical compositions
  Patent 8,968,753
  Issued: March 3, 2015
  Inventor(s): Terracciano Joseph & Damour Nicole Miller & Jiang Chun & Fogliato Giovanni & Donadelli Giuseppe Alessandro & Resemini Dario
  Assignee(s): Calixa Therapeutics, Inc.
  

  Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
  • March 14, 2034
    
    ✓ 
    Patent use: COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
  • March 14, 2034
    
    ✓ 
    Patent use: COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
• Ceftolozane-tazobactam pharmaceutical compositions
  Patent 9,320,740
  Issued: April 26, 2016
  Inventor(s): Terracciano Joseph & Damour Nicole Miller & Jiang Chun & Fogliato Giovanni & Donadelli Giuseppe Alessandro & Resemini Dario
  Assignee(s): MERCK SHARP & DOHME CORP.
  

  Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Drug product
• Methods for treating intrapulmonary infections
  Patent 9,724,353
  Issued: August 8, 2017
  Inventor(s): Chandorkar Gurudatt A. & Huntington Jennifer A. & Parsons Tara & Umeh Obiamiwe C.
  Assignee(s): MERCK SHARP & DOHME CORP.
  

  This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.

  Patent expiration dates:

  • September 7, 2032
    
    ✓ 
    Patent use: TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
  • September 7, 2032
    
    ✓ 
    Patent use: TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
• Ceftolozane antibiotic compositions
  Patent 9,872,906
  Issued: January 23, 2018
  Inventor(s): Terracciano Joseph & Damour Nicole Miller & Jiang Chun & Fogliato Giovanni & Donadelli Giuseppe Alessandro & Resemini Dario
  Assignee(s): Merck Sharp & Dohme Corp.
  

  This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 21, 2025 - NEW PATIENT POPULATION

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer